Ann: Atomo & Access Bio enter North American COVID-19 partnership, page-153

@dahoff as i have shared previously.

"Investors need realise the type of test that AT1 has produced is an"Antibody Test".

Antibody testscan only tell you if you have"had"the virus and not if you"have"the virus so in scenarios like you have pointed out above they are useless. It will not pick up if a passenger"has"the virus and is infectious so that passenger will go on the plane and most likely infect everyone else.

The type of test that would be used at airports, cruise liners etc would be an "Antigen Test".

Antigen testscan tell you if you"have"the virus and are much more valuable in stopping the spread.

Don't get confused between the two types of test. There are 100's of companies producing"Antibody Tests"but only a 3 or 4 companies developing"Antigen Tests"as they are so much harder to develop.

Research both as both tests have a place in today's pandemic but they do very different things.

There is another ASX listed company that a few weeks back announced a working"Antigen Test"that they are now progressing to commercialisation. I wont mention the name in case this is seen as cross promotion (i don't hold either) but they are worth researching along with AT1 so you can see the vast difference between the 2 tests and how they work.

Good on AT1 for what they have produced but lets not accidentally confuse the two tests and their capabilities."